<DOC>
	<DOCNO>NCT03019627</DOCNO>
	<brief_summary>The phase II study single-center , randomize , double-masked , parallel-arm , vehicle-controlled trial , design evaluate safety efficacy Recombinant Human Nerve Growth Factor ( rhNGF ) eye drop 20 μg/ml concentration administer six time daily 8 week patient dry eye .</brief_summary>
	<brief_title>An 8-week Study Evaluate Safety Efficacy Recombinant Human Nerve Growth Factor ( rhNGF ) Eye Drops Solution Versus Vehicle Patients With Dry Eye</brief_title>
	<detailed_description>The propose phase II study single-center , randomize , double-masked , parallel-arm , vehicle-controlled trial , design evaluate safety efficacy Recombinant Human Nerve Growth Factor ( rhNGF ) eye drop 20 μg/ml concentration administer six time daily 8 week patient dry eye . After confirmation inclusion exclusion criterion eligible patient randomize 2:1 ratio rhNGF vehicle control treatment 8 week study treatment administration 4 week Follow-up .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Patients ( male female ) must ≥ 18 year age . 2 . Patients must diagnose type dry eye ( e.g . Meibomian Gland Dysfunction , Blepharitis , Keratoconjunctivitis sicca etc ) least 3 month enrollment . 3 . Patients must present dry eye pathology characterize follow clinical feature : 1 . Corneal and/or conjunctival stain fluorescein lissamine green use National Eye Institute ( NEI ) grade system &gt; 3 2 . Mean Symptom Assessment Dry Eye ( SANDE ) questionnaire ≥30 3 . Schirmer test without anesthesia &lt; 10 mm/5 minute and/or tear film breakup time ( TFBUT ) &lt; 10 second study eye 4 . The eye ( study eye ) must fulfill criterion . 5 . Patients must best correct distance visual acuity ( BCDVA ) score ≥ 0.1 decimal unit eye time study enrollment . 6 . Female patient must negative pregnancy test childbirth potential . 7 . Only patient satisfy requirement inform consent may include study . Written Informed Consent must obtain initiation study specific procedure . 8 . Patients must ability willingness comply study procedure . 1 . Best correct distance visual acuity ( BCDVA ) score &lt; 0.1 decimal unit either eye . 2 . Evidence active ocular infection either eye . 3 . Presence history ocular disorder condition , include ocular surgery , trauma , disease could possibly interfere interpretation study result opinion Investigator . 4 . Intraocular inflammation define Tyndall score &gt; 0 . 5 . Active recent diagnosis malignancy ( i.e. , currently chemo/radiotherapy ) . 6 . Systemic disease stabilize within 1 month baseline visit ( e.g. , uncontrolled diabetes ; thyroid malfunction ) judge Investigator incompatible study ( e.g. , current systemic infection ) condition incompatible frequent assessment require study . 7 . Patients serious adverse reaction significant hypersensitivity drug chemically related compound , clinically significant allergy drug , food , amide local anesthetic , material , include commercial artificial tear contain carboxymethylcellulose ( CMC ) ( opinion Investigator ) . 8 . Use topical cyclosporine , topical corticosteroid , topical medication treatment dry eye either eye day study enrollment . 9 . Contact lenses punctal plug use study ( previous use exclusion criterion , must discontinue baseline visit . 10 . An anticipated need additional systemic treatment dry eye study ( prior treatment must continue entire duration study ) . 11 . Females childbearing potential ( surgically sterilize postmenopausal least 1 year ) exclude participation study meet one follow condition : 1. currently pregnant , 2. positive result urine pregnancy test ( Baseline/Day 0 ) , 3. intend become pregnant study treatment period , 4. breastfeeding , 5. willing use highly effective birth control measure , : hormonal contraceptive oral , implanted , transdermal , injected and/or mechanical barrier method spermicide conjunction barrier condom diaphragm intrauterine device ( IUD ) entire course 30 day study treatment period . 12 . History drug addiction alcohol abuse . 13 . Any prior ocular surgery ( include refractive palpebral cataract surgery ) within 90 day screen visit . 14 . Participation clinical trial new active substance past 30 day . 15 . Participation another clinical trial study time present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>